Thu, May 13, 2021
Wed, May 12, 2021
Tue, May 11, 2021

Colin Bristow Maintained (VRTX) at Strong Buy with Increased Target to $279 on, May 12th, 2021

Colin Bristow of UBS, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $278 to $279 on, May 12th, 2021.

Colin has made no other calls on VRTX in the last 4 months.



There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 2 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $254 on, Friday, April 30th, 2021
  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $250 on, Tuesday, February 2nd, 2021


These are the ratings of the 7 analyists that currently disagree with Colin


  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $260 on, Monday, May 3rd, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $262 on, Friday, April 30th, 2021
  • Gena Wang of "Barclays" Maintained at Buy and Held Target at $302 on, Wednesday, April 21st, 2021
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $252 on, Tuesday, April 20th, 2021
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $284 on, Tuesday, February 2nd, 2021
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $347 on, Tuesday, February 2nd, 2021
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $280 on, Tuesday, February 2nd, 2021